Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18329485 | 0.86 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2MAPK1NOTUM | |
| SCHEMBL19585479 | 0.84 | KMT2A (0.40) | MEN1KMT2ASMN1; SMN2MAPK1CES2 | |
| SCHEMBL17897046 | 0.83 | METAP2 (0.47) | MEN1KMT2ASMN1; SMN2MAPK1CES2 | |
| SCHEMBL697516 | 0.83 | PKM (0.39) | MEN1KMT2ASMN1; SMN2MAPK1CES2 | |
| SCHEMBL20780583 | 0.83 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2MAPK1CES2 | |
| SCHEMBL365563 | 0.81 | CES2 (0.47) | MEN1KMT2ASMN1; SMN2CES2CES1 | |
| SCHEMBL31258574 | 0.81 | CES2 (0.47) | MEN1KMT2ASMN1; SMN2CES2CES1 | |
| SCHEMBL25046254 | 0.81 | CES2 (0.37) | MEN1KMT2ASMN1; SMN2MAPK1CES2 | |
| SCHEMBL9789269 | 0.81 | CCNB2 (0.38) | MEN1KMT2AMAPK1CES2CES1 | |
| SCHEMBL9381963 | 0.81 | CA12 (0.46) | MEN1KMT2ASMN1; SMN2MAPK1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025096453-A1 | COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2024201308-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | 주식회사 엘지화학 | 2024-10-03 | — | — | WO | disclosed |
| CN-114206870-B | Tricyclic AKR1C 3-dependent KARS inhibitors | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | NOVARTIS AG (CH) | 2024-04-30 | — | — | US | disclosed |
| EP-4349839-A2 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| CN-117486753-A | Fluorine-containing benzoyl diethylamine compound with mosquito repellent effect, method and application thereof in mosquito repellent | 天津科技大学 | 2024-02-02 | — | — | CN | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009002808-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-3985799-A | 2-Fluoro-6-trifluoromethylbenzoic acid | SANDOZ, INC. (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | MEN1 4319/4885KMT2A 4052/4885SMN1; SMN2 1596/4885 |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | MEN1 1270/4885KMT2A 2190/4885SMN1; SMN2 3248/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | MEN1 4630/4885KMT2A 1409/4885SMN1; SMN2 3655/4885 |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | AKR1C2, AKR1B1, AKR1C1 | MEN1 4630/4885KMT2A 1409/4885SMN1; SMN2 3655/4885 |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | MEN1 4630/4885KMT2A 1409/4885SMN1; SMN2 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.